Navigation Links
Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles Officials and Dignitaries
Date:1/13/2009

Grifols welcomes Los Angeles Mayor Antonio Villaraigosa, Cal State LA President James Rosser, Councilman Hose Huizar, patient representatives and other dignitaries for the construction dedication ceremony of its new IVIG facility.

LOS ANGELES, Jan. 13 /PRNewswire/ -- Today, Grifols SA (Grifols), a global healthcare company based in Barcelona, Spain, Grifols welcomes Los Angeles Mayor Antonio Villaraigosa., Cal State LA President James Rosser, Councilman Jose Huizar and other elected officials, patient representatives and dignitaries for the ceremonial dedication of its new IVIG facility. Grifols, a global healthcare company based in Barcelona, Spain, recently broke ground on a new 92,000 square foot, intravenous immune globulin (IVIG) production facility at its US headquarters in East Los Angeles. This new facility is the initial realization of its $600 million long-range investment plan announced in October 2007 to increase production for Grifols lifesaving therapies.

The new facility represents a $135 million investment in its facility in El Sereno and will provide approximately 300 new high-paying jobs to Los Angeles. "We are committed to growing Grifols operations in Los Angeles and to giving back to the community through the creation of new quality jobs and economic growth" said Gregory Rich, President of Grifols, Inc.

"Without the support of Mayor Villaraigosa and his business team, we would not have been able to make our vision a reality in Los Angeles. This is the first step in our long-range growth plans for Los Angeles and to meet increasing patient needs for lifesaving plasma therapies."

"The bio-med industry is a critical component of the economic engine of Los Angeles and I am pleased to support Grifols expansion and investment in our great city. As the bio-med sector continues to grow, it will provide good, high-wage jobs for Angelinos. I am glad that we were instrumental in supporting Grifols expansion and allowing them to double their production capacity for their lifesaving therapies" said Mayor Antonio R. Villaraigosa.

"We commend Grifols' increased commitment to the production of immune globulin therapy. Assuring continued access to this lifesaving medicine means countless people who live with primary immunodeficiencies, such as my son, can lead healthy and productive lives," said Marcia Boyle, President and Founder of the Immune Deficiency Foundation, the national patient organization for persons with primary immune diseases.

Demand for IVIG has seen steady growth over the past ten years in the US, Europe and other international markets. The dedication ceremony took place at Grifols' US production campus and US corporate offices at 2410 Lillyvale, Los Angeles on Tuesday, January 13, 2009 at 11:00 a.m. This unique event brought together elected officials, representatives from national patient organizations, and Grifols officials to celebrate the company's efforts to ensure continued access to life-saving plasma medicines including IVIG.

About Grifols

Grifols SA (Grifols) is a global healthcare company founded in 1940 in Barcelona, Spain. Today Grifols products and services are provided in more than 90 countries around the world. Grifols specializes in the production of plasma therapies to treat a variety of life-threatening diseases and conditions. Grifols operates 80 plasma donor centers throughout the US and has manufacturing facilities located in Barcelona, Spain and Los Angeles, California. For more information about Grifols please visit www.grifols.com or contact:


'/>"/>
SOURCE Grifols SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Grifols Biomat USA Opens New Plasma Donor Center in Lincoln
2. Coalition for Pulmonary Fibrosis Celebrates Landmark Year for Awareness, Advocacy, Research
3. Glaucoma Research Foundation Celebrates National Glaucoma Awareness Month
4. Cystic Fibrosis Services Pharmacy Celebrates 20th Anniversary
5. Mental Health America Celebrates 100 Years of Mental Health Advocacy and Support
6. Retired Heart Surgeon Dr. Dwight Lundell Celebrates 65th Birthday by Placing First in Arizona Ironman Competition
7. Cloned Canine Celebrates Her 1st Birthday
8. Blue Shield of California Celebrates Completion of New Lodi Campus
9. Tenegar Town Celebrates Dedication Of New Clinic As Beacon Of Hope
10. Florida's Natural Celebrates 75 Years with Record Performance
11. Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: